About Aptevo Therapeutics (NASDAQ:APVO)
Aptevo Therapeutics Inc., a biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed products include IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations; and WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn. The company's marketed products also comprise HepaGam B used for the prevention of hepatitis-B recurrence following liver transplantation in HBsAg-positive liver transplant patients, and for the treatment following exposure to hepatitis-B; and VARIZIG for use in treating following exposure to varicella zoster virus, which causes chickenpox in high-risk individuals. Its investigational stage product candidates include MOR209/ES414, a bispecific immunotherapeutic protein that is in Phase I clinical trial for metastatic castration-resistant prostate cancer; ES210, a bispecific protein therapeutic that is in pre-clinical development stage for inflammatory bowel diseases; otlertuzumab, a monospecific protein therapeutic that is in Phase II clinical trial for chronic lymphocytic leukemia; ROR1, a bispecific immunotherapeutic protein that is in preclinical development; APVO436, a bispecific protein therapeutic, which is in pre-clinical development; and other therapeutic protein product candidates for cancer. The company was incorporated in 2016 and is based in Seattle, Washington.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:APVO
CUSIPN/A
Phone206-838-0500
Debt
Debt-to-Equity Ratio0.19%
Current Ratio5.14%
Quick Ratio5.08%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$14.66 million
Price / Sales6.19
Cash FlowN/A
Price / CashN/A
Book Value$3.83 per share
Price / Book1.12
Profitability
EPS (Most Recent Fiscal Year)($1.53)
Net Income$6.97 million
Net Margins5.40%
Return on Equity-45.72%
Return on Assets-30.14%
Miscellaneous
Employees121
Outstanding Shares21,110,000
Aptevo Therapeutics (NASDAQ:APVO) Frequently Asked Questions
What is Aptevo Therapeutics' stock symbol?
Aptevo Therapeutics trades on the NASDAQ under the ticker symbol "APVO."
How were Aptevo Therapeutics' earnings last quarter?
Aptevo Therapeutics (NASDAQ:APVO) posted its quarterly earnings results on Thursday, August, 10th. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.61) by $0.08. The biotechnology company had revenue of $10.76 million for the quarter. Aptevo Therapeutics had a net margin of 5.40% and a negative return on equity of 45.72%. View Aptevo Therapeutics' Earnings History.
When is Aptevo Therapeutics' next earnings date?
What price target have analysts set for APVO?
2 brokerages have issued twelve-month price objectives for Aptevo Therapeutics' stock. Their forecasts range from $6.00 to $12.00. On average, they anticipate Aptevo Therapeutics' stock price to reach $9.00 in the next year. View Analyst Ratings for Aptevo Therapeutics.
Who are some of Aptevo Therapeutics' key competitors?
Some companies that are related to Aptevo Therapeutics include Kamada (KMDA), Spring Bank Pharmaceuticals (SBPH), Proteostasis Therapeutics (PTI), Immune Design (IMDZ), Avid Bioservices (CDMO), Intec Pharma (NTEC), XBiotech (XBIT), NewLink Genetics (NLNK), Newron Pharmaceuticals (NWPHF), Teligent (TLGT), Tetraphase Pharmaceuticals (TTPH), Acer Therapeutics (ACER), Aeglea Bio Therapeutics (AGLE), Sierra Oncology (SRRA), Aldeyra Therapeutics (ALDX), Zynerba Pharmaceuticals (ZYNE), BioXcel Therapeutics (BTAI) and Affimed (AFMD).
Who are Aptevo Therapeutics' key executives?
Aptevo Therapeutics' management team includes the folowing people:
- Mr. Marvin L. White, Chief Exec. Officer, Pres and Director (Age 56)
- Mr. Jeffrey G. Lamothe CA, Chief Financial Officer, Sr. VP and Treasurer (Age 52)
- Dr. Scott C. Stromatt M.D., Chief Medical Officer and Sr. VP of Clinical Devel. & Medical Affairs (Age 60)
- Mr. Randy Joe Maddux, Sr. VP of Operations (Age 57)
- Dr. Jane A. Gross Ph.D., Chief Scientific Officer and Sr. VP (Age 61)
Has Aptevo Therapeutics been receiving favorable news coverage?
News stories about APVO stock have been trending somewhat negative this week, Accern Sentiment reports. The research firm identifies positive and negative press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Aptevo Therapeutics earned a media sentiment score of -0.06 on Accern's scale. They also gave news articles about the biotechnology company an impact score of 47.37 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
How do I buy shares of Aptevo Therapeutics?
Shares of APVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aptevo Therapeutics' stock price today?
One share of APVO stock can currently be purchased for approximately $4.30.
How big of a company is Aptevo Therapeutics?
Aptevo Therapeutics has a market capitalization of $94.16 million and generates $14.66 million in revenue each year. The biotechnology company earns $6.97 million in net income (profit) each year or ($1.53) on an earnings per share basis. Aptevo Therapeutics employs 121 workers across the globe.
How can I contact Aptevo Therapeutics?
Aptevo Therapeutics' mailing address is 2401 4TH AVENUE SUITE 1050, SEATTLE WA, 98121. The biotechnology company can be reached via phone at 206-838-0500 or via email at [email protected]
MarketBeat Community Rating for Aptevo Therapeutics (APVO)
MarketBeat's community ratings are surveys of what our community members think about Aptevo Therapeutics and other stocks. Vote "Outperform" if you believe APVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APVO will underperform the S&P 500 over the long term. You may vote once every thirty days.
Aptevo Therapeutics (NASDAQ:APVO) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
2 Wall Street analysts have issued ratings and price targets for Aptevo Therapeutics in the last 12 months. Their average twelve-month price target is $9.00, suggesting that the stock has a possible upside of 109.30%. The high price target for APVO is $12.00 and the low price target for APVO is $6.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $9.00 | $6.00 | $6.00 | $6.00 |
| Price Target Upside: | 109.30% upside | 158.62% upside | 158.62% upside | 158.62% upside |
Aptevo Therapeutics (NASDAQ:APVO) Consensus Price Target History
Aptevo Therapeutics (NASDAQ:APVO) Analyst Ratings History
Show:
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 4/11/2018 | Roth Capital | Initiated Coverage | Buy | $12.00 | High |  |
| 10/5/2017 | Piper Jaffray | Reiterated Rating | Overweight -> Overweight | $6.00 | N/A | |
(Data available from 4/20/2016 forward)
Aptevo Therapeutics (NASDAQ:APVO) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Aptevo Therapeutics (NASDAQ APVO) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 15.60%
Institutional Ownership Percentage: 33.04%
Aptevo Therapeutics (NASDAQ APVO) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/19/2018 | Marvin L White | Insider | Sell | 100,000 | $2.93 | $293,000.00 | | |
| 11/15/2017 | Randy Joe Maddux | VP | Buy | 25,000 | $2.76 | $69,000.00 | 25,000 | |
(Data available from 1/1/2013 forward)
Aptevo Therapeutics (NASDAQ APVO) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Aptevo Therapeutics’ Bispecific Antibody APVO436 Shows Robust T-Cell Activation With Minimal Cytokine Release
www.nasdaq.com - April 16 at 9:37 AM |
 | Aptevo Therapeutics’ Bispecific Antibody APVO436 Shows Robust T-Cell Activation With Minimal Cytokine Release
finance.yahoo.com - April 16 at 9:37 AM |
 | Aptevo Therapeutics (APVO) Downgraded by ValuEngine
www.americanbankingnews.com - April 14 at 2:30 PM |
| Analysts Expect Aptevo Therapeutics Inc (APVO) to Announce ($0.76) Earnings Per Share
www.americanbankingnews.com - April 13 at 5:23 AM |
| Aptevo Therapeutics (APVO) Now Covered by Analysts at Roth Capital
www.americanbankingnews.com - April 11 at 9:26 AM |
| Aptevo Therapeutics (APVO) Rating Increased to Sell at ValuEngine
www.americanbankingnews.com - April 9 at 11:35 AM |
| Aptevo Therapeutics Inc (APVO) Expected to Announce Earnings of -$0.76 Per Share
www.americanbankingnews.com - April 7 at 5:15 AM |
| Zacks: Aptevo Therapeutics Inc (APVO) Receives Consensus Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - March 29 at 9:16 PM |
| Zacks: Aptevo Therapeutics Inc (APVO) Given Consensus Recommendation of "Strong Buy" by Analysts
www.americanbankingnews.com - March 25 at 8:56 AM |
| Aptevo Therapeutics Inc (APVO) Insider Sells $293,000.00 in Stock
www.americanbankingnews.com - March 21 at 1:26 PM |
| Aptevo Therapeutics Reports 2017 Financial Results and Provides Business Update
finance.yahoo.com - March 13 at 10:04 AM |
| Aptevo Therapeutics Presents New Patient-Reported Data With IXINITY
finance.yahoo.com - March 12 at 10:33 AM |
| Zacks: Analysts Set $6.00 Target Price for Aptevo Therapeutics Inc (APVO)
www.americanbankingnews.com - March 8 at 3:12 AM |
| Aptevo Therapeutics Inc (APVO) Expected to Announce Earnings of -$0.32 Per Share
www.americanbankingnews.com - March 4 at 1:08 AM |
| Aptevo Therapeutics Inc (APVO) Given Average Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - March 3 at 5:15 AM |
| Head-To-Head Comparison: Aptevo Therapeutics (APVO) vs. MannKind (MNKD)
www.americanbankingnews.com - March 2 at 12:08 PM |
| Aptevo Therapeutics to Present at the 30th Annual ROTH Conference
finance.yahoo.com - February 27 at 9:43 AM |
| Bioblast Pharma (ORPN) versus Aptevo Therapeutics (APVO) Financial Review
www.americanbankingnews.com - February 18 at 1:44 PM |
| Analysts Expect Aptevo Therapeutics Inc (APVO) to Announce ($0.32) Earnings Per Share
www.americanbankingnews.com - February 15 at 3:12 PM |
| Aptevo Therapeutics Inc (APVO) Expected to Post Earnings of -$0.32 Per Share
www.americanbankingnews.com - February 15 at 1:34 PM |
| Zacks: Aptevo Therapeutics Inc (APVO) Receives Average Rating of "Strong Buy" from Brokerages
www.americanbankingnews.com - February 10 at 3:28 PM |
| -$0.32 Earnings Per Share Expected for Aptevo Therapeutics Inc (APVO) This Quarter
www.americanbankingnews.com - January 29 at 11:20 AM |
| Zacks: Analysts Set $6.00 Price Target for Aptevo Therapeutics Inc (APVO)
www.americanbankingnews.com - January 26 at 10:52 AM |
| Aptevo Therapeutics Inc (APVO) Receives Average Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - January 20 at 9:14 PM |
| Report: Exploring Fundamental Drivers Behind Anthera Pharmaceuticals, Alarm, Aptevo Therapeutics, Shoe Carnival, Independent Bank, and First Internet — New Horizons, Emerging Trends, and Upcoming Developments
finance.yahoo.com - January 17 at 10:36 AM |
| Zacks: Analysts Anticipate Aptevo Therapeutics Inc (APVO) Will Announce Earnings of -$0.32 Per Share
www.americanbankingnews.com - January 12 at 1:06 PM |
 | Aptevo Therapeutics (APVO) Commences Patient Dosing in Phase 2 Clinical Trial of Otlertuzumab in Peripheral T-Cell Lymphoma
www.streetinsider.com - January 9 at 4:18 PM |
| Aptevo Therapeutics Begins Patient Dosing in Phase 2 Clinical Trial of Otlertuzumab in Peripheral T-Cell Lymphoma
finance.yahoo.com - January 8 at 10:51 AM |
| Aptevo Therapeutics Inc (APVO) Given $6.00 Consensus Price Target by Brokerages
www.americanbankingnews.com - January 5 at 5:50 PM |
| Aptevo Therapeutics, Inc. :APVO-US: Earnings Analysis: Q3, 2017 By the Numbers : January 3, 2018
finance.yahoo.com - January 3 at 9:54 AM |
| Analysts Anticipate Aptevo Therapeutics Inc (APVO) to Announce ($0.32) Earnings Per Share
www.americanbankingnews.com - January 2 at 9:42 PM |
| Aptevo Therapeutics Inc (APVO) Short Interest Update
www.americanbankingnews.com - January 1 at 1:16 AM |
| Aptevo Therapeutics (APVO) & Kindred Biosciences (KIN) Head to Head Comparison
www.americanbankingnews.com - December 27 at 7:30 PM |
| ETFs with exposure to Aptevo Therapeutics, Inc. : December 27, 2017
finance.yahoo.com - December 27 at 4:55 PM |
| -$0.32 EPS Expected for Aptevo Therapeutics Inc (APVO) This Quarter
www.americanbankingnews.com - December 26 at 9:16 PM |
| Does Aptevo Therapeutics Inc’s (NASDAQ:APVO) 74.9% EPS Growth Reflect The Long-Term Trend?
finance.yahoo.com - December 19 at 10:45 AM |
| Analysts Anticipate Aptevo Therapeutics Inc (APVO) to Announce ($0.32) EPS
www.americanbankingnews.com - December 15 at 5:52 AM |
| ETFs with exposure to Aptevo Therapeutics, Inc. : December 11, 2017
finance.yahoo.com - December 11 at 4:23 PM |
| Aptevo Therapeutics’ Novel Bispecific Antibody Therapeutic APVO436 Shows Broad Activity in Primary Human AML Samples
finance.yahoo.com - December 11 at 11:22 AM |
| Aptevo Therapeutics Inc. (APVO) VP Randy Joe Maddux Acquires 25,000 Shares
www.americanbankingnews.com - December 8 at 11:16 PM |
| Aptevo Therapeutics Inc. (APVO) Given Consensus Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - November 30 at 11:46 PM |
| Aptevo Therapeutics (APVO) to Conduct Phase 2 Study of Otlertuzumab in PTCL
www.streetinsider.com - November 30 at 4:15 PM |
| ETFs with exposure to Aptevo Therapeutics, Inc. : November 29, 2017
finance.yahoo.com - November 29 at 4:15 PM |
| Financial Analysis: Aptevo Therapeutics (APVO) versus Array BioPharma (ARRY)
www.americanbankingnews.com - November 28 at 9:08 PM |
| Is Aptevo Therapeutics Inc’s (APVO) Balance Sheet Strong Enough To Weather A Storm?
finance.yahoo.com - November 21 at 9:35 PM |
| Brokerages Anticipate Aptevo Therapeutics Inc. (APVO) to Announce ($0.66) EPS
www.americanbankingnews.com - November 15 at 11:24 PM |
| Aptevo Therapeutics to Present at the 29th Annual Piper Jaffray Healthcare Conference
finance.yahoo.com - November 14 at 4:25 PM |
| Short Interest in Aptevo Therapeutics Inc. (APVO) Rises By 31.1%
www.americanbankingnews.com - November 13 at 2:32 AM |
| Aptevo Therapeutics Inc. (APVO) Lowered to "Sell" at ValuEngine
www.americanbankingnews.com - November 11 at 7:38 PM |
| Zacks: Analysts Set $6.00 Price Target for Aptevo Therapeutics Inc. (APVO)
www.americanbankingnews.com - November 9 at 5:30 PM |
Aptevo Therapeutics (NASDAQ:APVO) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Aptevo Therapeutics (NASDAQ:APVO) Income Statement, Balance Sheet and Cash Flow Statement
Aptevo Therapeutics (NASDAQ APVO) Stock Chart for Friday, April, 20, 2018
Loading chart…
